Ebola virus particle In an attempt to fight the outbreak of ebola in West Africa, the FDA has approved a limited use of a new drug composed of three humanized monoclonal antibodies. The drug, which is being developed by Mapp Biopharmaceutical (1), has not yet reached the clinic but the importance of the drug for stopping the Ebola outbreak in West Africa has forced the FDA to grant it viable for limited use before all tests have been carried out.
The number of FDA approved humanized antibodies for therapeutic treatments are now in the thirties, and hundreds of antibody therapies are undergoing clinical trials. Capra Science Antibodies AB is a trusted partner in the development of humanized antibodies for health care. The expertise of the Capra Science team includes the range of steps including monoclonal antibody generation, humanization process, antibody production for R&D and pre-clinical evaluation.
(1)ZMapp was developed as a result of the collaboration between Mapp Biopharmaceutical, LeadBio, Defyrus and US government and Canadian Public Health Agency of Canada.
The number of FDA approved humanized antibodies for therapeutic treatments are now in the thirties, and hundreds of antibody therapies are undergoing clinical trials. Capra Science Antibodies AB is a trusted partner in the development of humanized antibodies for health care. The expertise of the Capra Science team includes the range of steps including monoclonal antibody generation, humanization process, antibody production for R&D and pre-clinical evaluation.
(1)ZMapp was developed as a result of the collaboration between Mapp Biopharmaceutical, LeadBio, Defyrus and US government and Canadian Public Health Agency of Canada.
RSS Feed